MOLOGEN AG / Key word(s): Study
30.03.2012 07:46
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad-hoc-Announcement of 03/30/2012
MOLOGEN AG: Treatment with renal cancer therapy MGN1601 generates clear
survival benefit for patients
- First evaluation of survival times provides results that exceed
expectations
- Immunological active principle proven in an exemplary manner
In a further evaluation of the phase I/II renal cancer study with MGN1601,
the biotechnology company MOLOGEN AG has analyzed the survival times of
patients enrolled in the study and the first data of the accompanying
immunological tests. The result: patients that were able to completely
finish the twelve-week therapy scheme scheduled in the study protocol with
the study drug MGN1601 (PP group) have an unexpectedly clear survival
benefit in comparison with patients that had to terminate their study
therapy early (non-PP group).
Thus far, the ten patients in the PP group already survived more than ten
months on average. Since only one patient in this group has died by now,
this parameter will continue to improve. In the non-PP group, the median
survival time is a little over two months; all nine patients had died at
the latest after six months. With regard to historical clinical data and
statistical models, a median survival time of five to seven months was
expected. Hence, this was clearly exceeded in this study.
Furthermore it is very remarkable that for two patients who are currently
being treated in the extension phase of the study at fixed intervals, the
disease has not progressed in over ten months.
Immunological principle proven in an exemplary manner
With the evaluation of immunological data it was possible to prove in an
exemplary manner that those patients that completed the entire planned
three-month treatment cycle with MGN1601 in accordance with the study
protocol have generated a clear immune response. The strength of the immune
response increased with continued treatment. With these results, the
mechanism of action demonstrated in preclinical studies could also be
confirmed in patients. In the view of MOLOGEN AG, the observed positive
effects with respect to overall survival can thus be attributed to the
treatment with MGN1601.
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
About MOLOGEN AG
MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin
specializes in the research and development of innovative medications on
the basis of DNA structures. The activities focus on numerous product
developments which are relevant to the immune system; on the one hand
vaccines against infectious diseases and on the other hand cancer
medications. MOLOGEN AG is globally one of the few biotechnology companies
with well tolerated DNA-based cancer treatment in the clinical development
phase.
The stocks of MOLOGEN AG (ISIN DE0006637200) are listed in the Prime
Standard of the German stock exchange.
Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for
the Promotion of Science and Humanities in Germany | Association of
German biotechnology companies (VBU) | Association of researching
manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical
industry e.V. (VCI)
MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.
MOLOGEN AG
PRESS SERVICE:
Prof. Peter W. Huebner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Tel: +49 - 30 - 84 17 88 - 50
huebner@mologen.com
INVESTOR RELATIONS:
Joerg Petrass
Tel: +49 - 30 - 84 17 88 - 13
Tel: +49 - 30 - 84 17 88 - 50
investor@mologen.com
External Investor Relations:
Kirchhoff Consult AG
Sebastian Bucher
T: +49 - 40 - 60 91 86 - 18
F: +49 - 40 - 60 91 86 -16
sebastian.bucher@kirchhoff.de
Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.
30.03.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MOLOGEN AG
FabeckstraÃe 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: info@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: MOLOGEN AG: Treatment with renal cancer therapy MGN1601 generates clear survival benefit for patients
| Source: EQS Group AG